BidaskClub downgraded shares of Horizon Pharma (NASDAQ:HZNP) from a buy rating to a hold rating in a report published on Tuesday morning.

Other equities analysts have also recently issued reports about the company. Jefferies Group reissued a buy rating and set a $16.00 price target on shares of Horizon Pharma in a report on Thursday, October 5th. Cowen reissued a buy rating on shares of Horizon Pharma in a report on Thursday, September 28th. Goldman Sachs Group started coverage on Horizon Pharma in a report on Thursday, September 28th. They set a buy rating and a $16.00 price target on the stock. Cantor Fitzgerald reissued a buy rating and set a $17.00 price target on shares of Horizon Pharma in a report on Tuesday, September 26th. Finally, UBS Group set a $20.00 price target on Horizon Pharma and gave the company a buy rating in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $19.25.

Horizon Pharma (HZNP) traded up $0.20 during midday trading on Tuesday, hitting $14.82. The stock had a trading volume of 721,106 shares, compared to its average volume of 1,980,550. The company has a market cap of $2,440.00, a PE ratio of -4.88, a price-to-earnings-growth ratio of 0.71 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a 12-month low of $9.45 and a 12-month high of $17.69.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company’s revenue was up 30.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 EPS. analysts expect that Horizon Pharma will post 0.72 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in HZNP. Advantage Investment Management LLC raised its holdings in Horizon Pharma by 164.8% during the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,900 shares during the period. Family Management Corp bought a new stake in Horizon Pharma during the second quarter valued at about $131,000. Brown Advisory Inc. bought a new stake in Horizon Pharma during the third quarter valued at about $145,000. Prudential Financial Inc. raised its holdings in Horizon Pharma by 5.0% during the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 830 shares during the period. Finally, Amalgamated Bank raised its holdings in Horizon Pharma by 4.8% during the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 943 shares during the period. 86.58% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Horizon Pharma (HZNP) Stock Rating Lowered by BidaskClub” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/17/horizon-pharma-hznp-stock-rating-lowered-by-bidaskclub.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.